A Phase 1, Placebo-controlled, Randomized, Subject- And Investigator-blind, Sponsor-open, Crossover Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Pf-06266047 After Administration Of Single Ascending Doses To Healthy Adult Subjects

Trial Profile

A Phase 1, Placebo-controlled, Randomized, Subject- And Investigator-blind, Sponsor-open, Crossover Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Pf-06266047 After Administration Of Single Ascending Doses To Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2016

At a glance

  • Drugs PF 6266047 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 31 May 2016 Status changed from recruiting to completed.
    • 03 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 May 2016, according to ClinicalTrials.gov record.
    • 03 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 May 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top